Identification and management of persons with chronic viral hepatitis in the United States

Geoff Beckett, PA-C, MPH
CDC Division of Viral Hepatitis
Viral Hepatitis Prevention Board
19 March, 2010
Budapest

VHPB meeting "identification and management of chronic viral hepatitis in Europe" 18-19 march 2010, Budapest, Hungary.
The Burden of Chronic Hepatitis B and Hepatitis C in the U.S.

- **Persons living with chronic infection - ~ 4.5 M**
  - Chronic HBV: 800,00-1.4 million
  - Chronic HCV: 3.2 million
- **Chronic viral hepatitis associated deaths – 10,000-14,000**
  - Chronic HBV: 2,000-4,000 per yr
  - Chronic HCV: 8,000-10,000 per year
- **HIV infected**: 9% HBV; 25% HCV
- **Cause of most chronic liver disease in US**
Burden of Hepatitis B Virus Infection in the U.S.

<table>
<thead>
<tr>
<th>No. of Acute Clinical Cases Reported(^a)</th>
<th>2007</th>
<th>2006</th>
<th>2005</th>
<th>2004</th>
<th>2003</th>
<th>2002</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4,519</td>
<td>4,758</td>
<td>5,494</td>
<td>6,212</td>
<td>7,526</td>
<td>8,064</td>
</tr>
</tbody>
</table>

| Estimated No. of Acute Clinical Cases\(^b\) | 13,000| 13,000| 15,000| 17,000| 21,000| 23,000|

| Estimated No. of New Infections\(^b\) (current) | 43,000| 46,000| 53,000| 60,000| 73,000| 79,000|

<table>
<thead>
<tr>
<th>Percent Ever Infected(^c)</th>
<th>4.3% - 5.6%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Persons Living with Chronic Infection(^d)</td>
<td>800,000 - 1.4 million persons</td>
</tr>
<tr>
<td>Annual Number of Chronic Liver Disease Deaths associated with Viral Hepatitis(^e)</td>
<td>3,000</td>
</tr>
</tbody>
</table>
Prevalence of hepatitis B virus (HBV) infection, by risk population

<table>
<thead>
<tr>
<th>Population</th>
<th>Chronically infected with HBV*</th>
<th>Ever infected with HBV**</th>
</tr>
</thead>
<tbody>
<tr>
<td>General U.S. population</td>
<td>0.3 (95% CI: 0.2–0.4)</td>
<td>4.8% (95% CI: 4.2%-5.5%)</td>
</tr>
<tr>
<td>HIV-positive persons</td>
<td>4 – 17</td>
<td>24 – 76</td>
</tr>
<tr>
<td>Injection-drug users</td>
<td>3 – 6</td>
<td>20 – 70</td>
</tr>
<tr>
<td>Men who have sex with men</td>
<td>1 – 3</td>
<td>10 – 40</td>
</tr>
<tr>
<td>Sexual contacts of HBsAg+ persons</td>
<td>3.5 – 9</td>
<td>25 – 59</td>
</tr>
<tr>
<td>Household contacts of HBsAg+ persons</td>
<td>3 – 20</td>
<td>15 – 60</td>
</tr>
</tbody>
</table>

*HBsAg+; **Total anti-HBc+
Burden of Hepatitis C Virus Infection in the U.S.

No. of Acute Clinical Cases Reported
- 2007: 849
- 2006: 802
- 2005: 694
- 2004: 758
- 2003: 891
- 2002: 1,223

Estimated No. of Acute Clinical Cases
- 2007: 2,800
- 2006: 3,200
- 2005: 3,400
- 2004: 4,200
- 2003: 4,500
- 2002: 4,800

Estimated No. of New Infections (current)
- 2007: 17,000
- 2006: 19,000
- 2005: 21,000
- 2004: 26,000
- 2003: 28,000
- 2002: 29,000

Percent Ever Infected
- 1.3% - 1.9%

Number of Persons Living with Chronic Infection
- 2.7–3.9 million persons

Annual Number of Chronic Liver Disease Deaths associated with Viral Hepatitis
- 12,000
Data Sources for HBV and HCV Incidence and Prevalence Estimates in the U.S.

a. Number of Acute Clinical Cases Reported:
For hepatitis A, hepatitis B, and hepatitis C/non-A, non-B hepatitis, the number of cases reported to the National Notifiable Disease Surveillance System (NNDSS).

b. Estimated Number of Acute Clinical Cases and New Infections:
Incidence estimates for hepatitis A and hepatitis B are derived from catalytic modeling of seroprevalence data from the Third National Health and Nutrition Examination Survey (NHANES III) applied to cases reported to the Nationally Notifiable Disease Surveillance System (NNDSS). Incidence estimates for hepatitis C are derived by adjusting rates from the Sentinel Counties Study of Viral Hepatitis (1982–2006) and Emerging Infection Program (2007) for underreporting and asymptomatic infection.

c. Percent Ever Infected:

d. Number of Persons Living with Chronic Infection:

e. Annual Number of Chronic Liver Disease Deaths associated with Viral Hepatitis:
**Primary prevention**
- Prevent nosocomial HBV transmission
- Manage exposures to HBV infected persons

**Secondary prevention**
Reduce risks for chronic liver disease in infected persons by providing medical management and antiviral treatment

**Recommendations based on:**
- Prevalence in population
- Serious outcomes from undetected infection
Low levels of Self-Awareness of Chronic HBV Infection

• As many as 2/3 of chronically-infected Asian Americans knew their status in several studies
Improve Screening and Care for Chronic Hepatitis C

• Improve screening strategies
  • Evaluate rapid HCV tests
    – Increase receipt of results and interventions
    – Integrate with HIV testing
  • Study alternatives to risk-based HCV screening
    – Age based or birth cohort screening
• Gather data on health care access and outcome
• Build model prevention and referral programs

Recommendations for Identification and Management of Persons with Chronic HBV Infection

- Testing recommendations
- Management guidance
- Infrastructure needs

VHPB meeting "identification and management of chronic viral hepatitis in Europe" 18-19 March 2010, Budapest, Hungary.
Chronic Viral Hepatitis and Health Disparities

- **Chronic HBV**
  - Asian/Pacific Islanders
    - 1 in 12 living with chronic HBV
    - Leading cause of cancer death
    - 40,000 cases per year among new entrants to US

- **Chronic HCV**
  - Most infections among persons born 1940-1965
  - Mortality twice that of whites for blacks, Hispanics, Native Americans
Prevalence of HCV RNA by Age and Race, United States
NHANES, 1999-2002

Estimated U.S. prevalence: 1.6% (3.2 million)

NHANES: Limitations

- Excludes incarcerated and homeless persons
  - Including incarcerated persons would increase the estimate of infected persons to 3.5 million
- Cross-sectional design prevents determination of sources of infection for individuals
- Possible under-reporting of injection drug use
CDC Recommendations for Identification and Management of Persons with Chronic HBV Infection (2008)

New

• persons born in geographic regions with HBsAg prevalence of ≥2%
• US born persons not vaccinated as infants whose parents were born in geographic regions with HBsAg prevalence of ≥8%
• injection-drug users
• men who have sex with men
• persons with elevated ALT/AST of unknown etiology
• persons with selected medical conditions who require immunosuppressive therapy

Continuing

• pregnant women
• infants born to HBsAg-positive mothers
• household contacts and sex partners of HBV-infected persons
• persons who are the source of blood or body fluid exposures that might warrant postexposure prophylaxis
• persons infected with HIV

VHPB meeting "Identification and management of chronic viral hepatitis in Europe" 18-19 march 2010, Budapest, Hungary.
### Recommendations for Routine Testing and Follow-up for Chronic Hepatitis B Virus (HBV) Infection

<table>
<thead>
<tr>
<th>Population</th>
<th>Testing</th>
<th>Vaccination/Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persons born in regions of high and intermediate HBV endemicity (HBeAg prevalence ≥2%)</td>
<td>Test for HBeAg, regardless of vaccination status in their country of origin, including: immigrants, refugees, asylum seekers, internationally adopted children.</td>
<td>If HBeAg positive, refer for medical management. If negative, assess for on-going risk for hepatitis B and vaccinate if indicated.</td>
</tr>
<tr>
<td>US born persons not vaccinated as infants whose parents were born in regions with high HBV endemicity (≥8%)</td>
<td>Test for HBeAg regardless of maternal HBeAg status if not vaccinated as infants in the United States.</td>
<td>If HBeAg positive, refer for medical management. If negative, assess for on-going risk for hepatitis B and vaccinate if indicated.</td>
</tr>
</tbody>
</table>

### Geographic Distribution of Chronic HBV Infection — Worldwide, 2006*

* For multiple countries, estimates of prevalence of hepatitis B surface antigen (HBeAg), a marker of chronic HBV infection, are based on limited data and might not reflect current prevalence in countries that have implemented childhood hepatitis B vaccination. In addition, HBeAg prevalence might vary within countries by subpopulation and locality.


---

VHPB meeting "identification and management of chronic viral hepatitis in Europe" 18-19 March 2010, Budapest, Hungary.
### Routine Testing and Follow-up for Chronic HBV Infection (continued)

<table>
<thead>
<tr>
<th>Population</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Injection-drug users</strong></td>
<td>Test for HBsAg, as well as for anti-HBc or anti-HBs to identify susceptible persons. First vaccine dose should be given at the same visit as testing. Susceptible persons should complete a 3-dose hepatitis B vaccine series to prevent infection from ongoing exposure.</td>
</tr>
<tr>
<td><strong>Men who have sex with men</strong></td>
<td>Test for HBsAg, as well as for anti-HBc or anti-HBs to identify susceptible persons. First vaccine dose should be given at the same visit as testing. Susceptible persons should complete a 3-dose hepatitis B vaccine series to prevent infection from ongoing exposure.</td>
</tr>
<tr>
<td><strong>Persons needing immunosuppressive therapy, including chemotherapy, immunosuppression related to organ transplantation, and immunosuppression for rheumatologic or gastrointestinal disorders</strong></td>
<td>Test for all markers of HBV infection (HBsAg, anti-HBc, and anti-HBs). Monitor closely persons who are HBsAg-positive for signs of liver disease.</td>
</tr>
<tr>
<td><strong>Persons with diverted NASH/ST of unknown etiology</strong></td>
<td>Test for HBsAg along with other appropriate medical evaluation. Follow-up as indicated.</td>
</tr>
<tr>
<td><strong>Donors of blood, plasma, organs, tissues, or semen</strong></td>
<td>Test for HBsAg, anti-HBc, and HBV-DNA as required. Vaccinate against hepatitis B to prevent transmission and reassess when serum anti-HBs titer falls below 10 mIU/mL.</td>
</tr>
<tr>
<td><strong>Hemodialysis patients</strong></td>
<td>Test for all markers of HBV infection (HBsAg, anti-HBc, and anti-HBs). Test vaccine nonresponders monthly for HBsAg. HBsAg-positive hemodialysis patients should be vaccinated.</td>
</tr>
<tr>
<td><strong>All pregnant women</strong></td>
<td>Test for HBsAg during each pregnancy, preferably in the first trimester. Test at the time of admission to labor if prenatal laboratory test result is not available or if mother was at risk for infection during pregnancy. If HBsAg-positive, refer for medical management. To prevent perinatal transmission, infants of HBsAg-positive mothers and unknown HBsAg status mothers should receive vaccination and postexposure prophylaxis in accordance with recommendations and within 12 hours of delivery.</td>
</tr>
<tr>
<td><strong>Infants born to HBsAg-positive mothers</strong></td>
<td>Test for HBsAg and anti-HBc 1–2 days after birth and at 1, 2, 6, and 12 months of age or at least 5 doses of a licensed hepatitis B vaccine series (i.e., at age 2, 4, 6, 10, and 14 months, respectively). At the end of the first year of age, test the child to assess effectiveness of postexposure prophylaxis. Testing should not be performed before age 9 months or within 1 month of the most recent vaccine dose. Vaccinate in accordance with recommendations.</td>
</tr>
<tr>
<td><strong>Household, needle-sharing, or sexual contacts of persons known to be HBsAg positive</strong></td>
<td>Test for HBsAg, as well as for anti-HBc or anti-HBs to identify susceptible persons. First vaccine dose should be given at the same visit as testing. Susceptible persons should complete a 3-dose hepatitis B vaccine series to prevent transmission from ongoing exposure.</td>
</tr>
<tr>
<td><strong>Persons who are the sources of blood or body fluids resulting in an exposure (e.g., needlestick, sexual assault) that might require postexposure prophylaxis</strong></td>
<td>Test for HBsAg. Vaccinate healthcare and public safety workers with reasonably anticipated occupational exposures to blood or infectious body fluids. Provide postexposure prophylaxis to exposed person if needed.</td>
</tr>
<tr>
<td><strong>HBV-positive persons</strong></td>
<td>Test for HBsAg, as well as for anti-HBc or anti-HBs to identify susceptible persons. Vaccinate susceptible persons against hepatitis B to prevent transmission.</td>
</tr>
</tbody>
</table>

Adapted from: Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 2004; 53(RR-16).
Recommendations for Identification and Management of Persons with Chronic HBV Infection

- **Testing recommendations**

- **Management guidance**
  - Patient counseling
  - Contact management
  - Referral for care and treatment

- **Infrastructure needs**
  - Community outreach
  - State/local prevention programs
  - Care capacity

VHPB meeting "Identification and management of chronic viral hepatitis in Europe" 18-19 March 2010, Budapest, Hungary.
Public health management of HBsAg-positive persons

- Development of testing programs and networks
- Contact management
- Patient education
- Medical management of chronic hepatitis B
  - Development of surveillance registries of persons with chronic HBV infection
Future Directions: implementation and monitoring recommendations

- Resources for testing/screening programs
- Resources for contact management
- Provider and patient education
- Improving Linkages to Care
- Development of surveillance and registries of persons with chronic HBV infection
In the United States, HCV Testing Routinely Recommended Based on Increased Risk for Infection

- Ever injected illegal drugs
-Received clotting factors made before 1987
-Received blood/organs before July 1992
-Ever on chronic hemodialysis
-Evidence of liver disease

MMWR 1998;47 (No. RR-19)
National HCV Prevention Strategy (2001)

- Prevent HCV infection
- Detect and control chronic liver disease
- Evaluate effectiveness of activities
- Conduct surveillance and research to advance hepatitis C prevention and control
Prevention of HCV infection

Primary = Prevent HCV Transmission

• High risk activities – IDU, high risk sex
• Nosocomial, occupational, transfusions and transplant

Secondary = Reduce Risk of Chronic Liver Disease

• Identify those at risk, test, counsel, medical management
NHANES follow-up survey, 2001-2002

101 anti-HCV+ persons interviewed

52 (51%) not aware of HCV status

49 (49%) knew HCV status

Reasons for previous testing (n=46) for anti-HCV included:

•21 (46%) routine physical/blood test
•6 (13%) blood donation
•5 (11%) evaluation of symptoms of viral hepatitis
•3 (7%) had an identified risk factor for HCV

FY 2008 Domestic Enacted Funds

Total: $1 billion

Domestic HIV 69%
STD 15%
TB 14%
Hepatitis 2%

Improve Screening and Care for Chronic Hepatitis C

- Improve screening strategies
  - Evaluate rapid HCV tests
    - Increase receipt of results and interventions
    - Integrate with HIV testing
  - Study alternatives to risk-based HCV screening
    - Age based or birth cohort screening
- Gather data on health care access and outcome
- Build model prevention and referral programs
### Outstanding issues

- How can incidence of HCV infection be reduced among IDU?
- How can non-hospital health care-related transmission be eliminated?
- What more can be learned about sexual transmission of HCV?
- How can we improve surveillance for both acute and chronic hepatitis C?
- **How can we most effectively identify HCV-infected persons?**
- Once identified, how can HCV-infected persons access care, as treatment improves?
Outstanding issues

- How can incidence of HCV infection be reduced among IDU?
- How can non-hospital health care-related transmission be eliminated?
- What more can be learned about sexual transmission of HCV?
- How can we improve surveillance for both acute and chronic hepatitis C?
- How can we most effectively identify HCV-infected persons?
- *Once identified, how can HCV-infected persons access care, as treatment improves?*
Treatment strategies

CDC does not issue treatment guidelines

AASLD PRACTICE GUIDELINES

• Chronic Hepatitis B: 2009
• Chronic Hepatitis C: 2009

• Major Health Services Issue: Linkage to Care
VHPB meeting "identification and management of chronic viral hepatitis in Europe" 18-19 March 2010, Budapest, Hungary.